According to the company’s most recent filing with the Securities and Exchange Commission, Barclays PLC decreased its stake in Unity Biotechnology Inc (NASDAQ: UBX) by 46.3 per cent in the third quarter. After selling 12,050 shares during the time, the fund owned 13,971 shares of the company’s share. As of its latest SEC filing, the holdings of Barclays PLC in Unity Biotechnology were worth $85,000.
More recently, a number of other hedge funds bought and sold UBX securities. During the first quarter, FMR LLC increased its stake in Unity Biotechnology by 18.2 per cent. After buying an additional 700,500 shares in the last quarter, FMR LLC now owns 4,551,523 shares of the company’s stock worth $36,913,000. During the second quarter, Aperio Group LLC bought a new stake in Unity Biotechnology shares valued at $50,000. Bank of Montreal Can increase its stake in Unity Biotechnology shares in the second quarter by 164,400.0 per cent. Bank of Montreal Can now own 4,935 stock shares valued at $47,000 after acquiring a further 4,932 shares over time. In the second quarter, Charles Schwab Investment Management Inc. raised its ownership of Unity Biotechnology by 12.1%. Charles Schwab Investment Management Inc. now owns 68,983 shares of the company’s stock worth $656,000 after the last quarter acquisition of an additional 7,463 shares. Eventually, during the second quarter, Bank of New York Mellon Corp increased its stake in Unity Biotechnology by 9.6%. Bank of New York Mellon Corp now owns 69,516 shares of the stock of the company worth $660,000 after purchasing a further 6,112 shares over time. Institutional investors and hedge funds own 35,56 per cent of the portfolio.
On UBX shares, multiple equity analysts have weighed in. In a research report on Monday, November 18, Mizuho reiterated a “buy” rating and set a $33.00 price target on Unity Biotechnology stock. In a research note on Thursday, December 12, Cantor Fitzgerald reaffirmed an “overweight” rating and set a target price of $20.00 for Unity Biotechnology stock. Finally, in a research report on Wednesday, December 18, Zacks Investment Research downgraded Unity Biotechnology’s stock from a “buy” rating to a “sell” rating. The stock was rated with a hold rating by one equity research analyst and four gave a buy rating to the stock. At the moment, the stock has a “Buy” consensus rating and an $18.81 consensus target price.
